Navigation Links
Newer Drug More Effective in Psoriasis Treatment
Date:1/13/2010

Stelara tops Enbrel in head-to-head comparison and requires fewer injections, researchers say,,

WEDNESDAY, Jan. 13 (HealthDay News) -- The estimated 7.5 million Americans suffering from psoriasis often have to tolerate long-term treatment that may be only moderately effective.

Now, a new drug called ustekinumab (Stelara) appears to be more effective than the old standby, etanercept (Enbrel), according to the results of a head-to-head comparison sponsored by the maker of Stelara.

"Ustekinumab is a more effective and faster acting therapy for psoriasis than the current biologic market leader for this condition," said lead researcher Dr. Christopher E.M. Griffiths, a professor of dermatology at the University of Manchester in England.

Enbrel and Stelara are biologic agents, which work by blocking proteins produced in the body. Enbrel blocks tumor necrosis factor alpha, while Stelara inhibits interleukin-12 and interleukin-23.

This is the first head-to-head trial of two biologic therapies for psoriasis, Griffiths noted. Psoriasis is a chronic, autoimmune disease that appears on the skin.

The report is published in the Jan. 14 issue of the New England Journal of Medicine. Centocor Research and Development sponsored the study.

For the study, Griffiths and colleagues randomly assigned 903 patients with moderate-to-severe psoriasis to two different doses of Stelara injected 30 days apart or to high-dose Enbrel injections twice a week for 12 weeks.

After 12 weeks of treatment, 67.5 percent of the patients receiving 45 milligrams of Stelara had a 75 percent improvement in their condition, according to the psoriasis area-and-severity index, as did 73.8 percent of those receiving 90 milligrams of Stelara.

Only 56.8 percent of those receiving Enbrel showed a similar improvement, the researchers found.

In addition, based on doctors' assessments, 65.1 percent
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
2. Newer Blood Thinners May Outperform Old Standbys
3. Newer heart devices significantly improve survival, complication rate and quality of life
4. Newer, Better Tests for Heart Attacks
5. Newer Drug Beats Tamoxifen for Older Breast Cancer Patients
6. The Other Cruciate Ligament: Newer Treatments for PCL Tears
7. Newer Blood Tests May Not Improve Heart Risk Assessment
8. FDA Panel OKs Newer Antipsychotics for Children
9. FDA Panel Mulls Newer Antipsychotics for Kids
10. Newer Antipsychotics May Boost Weight in Alzheimers Patients
11. Newer Sedative May Reduce Delirium in ICU Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 PreDiabetes ... PreD Store shoppers with a supply of ... meals to reduce post-meal blood sugar spikes. Learning how ... is an important part of a diabetes prevention plan. ... will receive one complimentary tube of sugardown. The offer ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
(Date:10/30/2014)... October 30, 2014 Horse Sense ... horseback riding to special needs individuals in the Jacksonville ... Saturday, November 15 from 10-2:00 p.m. at Bailey's Farm ... open to the public and is designed to raise ... Admission to the HSS Round-Up is free. Ticket purchases ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Facebook Websites In Thirty-Seconds 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2
... unreimbursed loss of as little as $500 would have ... As unemployment rates continue to climb, one often ... to affordable insurance. In a national recent survey conducted ... nearly two-thirds of respondents admitted to living paycheck-to-paycheck "often" ...
... Danaher Corporation (NYSE: DHR ... has approved a regular quarterly dividend of $0.03 ... holders of record on June 26, 2009.Danaher Corporation ... Technologies, Industrial Technologies and Tools and Components ( ...
... Fiscal third quarter revenue from continuing operations increased $25 million, or ... , , , , ... , , , , , ... , , , , , ...
... (Nasdaq: ABAX ), a medical products company manufacturing ... operations officer, will present at the Bank of America and ... 2009 at 10:00 a.m. ET. The conference will be held ... invited to listen to a live audio webcast of the ...
... Ohio, May 7 STERIS Corporation (NYSE: STE ... a 38% increase in its quarterly dividend to $0.11 per ... to shareholders of record at the close of business on ... of STERIS Corporation is to provide a healthier today and ...
... Patient-Centered Primary Care Collaborative is the National ... ,Medical Home,WELLINGTON, Fla. May 7 The ... has joined the Executive Committee of the ... is a collaboration of major employers, consumer ...
Cached Medicine News:Health News:Affinion Group Survey Reveals That Underinsured Consumers Need Alternate Solutions in Light of Current Economic Climate 2Health News:Affinion Group Survey Reveals That Underinsured Consumers Need Alternate Solutions in Light of Current Economic Climate 3Health News:Perrigo Reports Record Third Quarter 2Health News:Perrigo Reports Record Third Quarter 3Health News:Perrigo Reports Record Third Quarter 4Health News:Perrigo Reports Record Third Quarter 5Health News:Perrigo Reports Record Third Quarter 6Health News:Perrigo Reports Record Third Quarter 7Health News:Perrigo Reports Record Third Quarter 8Health News:Perrigo Reports Record Third Quarter 9Health News:Perrigo Reports Record Third Quarter 10Health News:Perrigo Reports Record Third Quarter 11Health News:Perrigo Reports Record Third Quarter 12Health News:Perrigo Reports Record Third Quarter 13Health News:Perrigo Reports Record Third Quarter 14Health News:Perrigo Reports Record Third Quarter 15Health News:Perrigo Reports Record Third Quarter 16Health News:Perrigo Reports Record Third Quarter 17Health News:Perrigo Reports Record Third Quarter 18Health News:Perrigo Reports Record Third Quarter 19Health News:Perrigo Reports Record Third Quarter 20Health News:Perrigo Reports Record Third Quarter 21Health News:Perrigo Reports Record Third Quarter 22Health News:Abaxis, Inc. to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 2Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 4Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 5Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 6
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
(Date:10/30/2014)... 2014 Today, DripDrop, the first great ... was awarded a two-year contract, effective Sept. 1, ... serves the more than 100,000 members and affiliates ... Provista.  DripDrop also received an ... hospitals who attended the recent Novation 2014 Innovative ...
(Date:10/30/2014)... NEW YORK , Oct. 29, 2014 /PRNewswire/ ... on the basis of test type, technology, product, ... to register the highest growth rate in the ... period. This high growth is attributed to various ... spectrometry is a fundamental instrument used for expanded ...
Breaking Medicine Technology:Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3
... SEATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Sciences, ... Phase III,AIR-CF2 study evaluating aztreonam lysine for ... (CF) who have,pulmonary Pseudomonas aeruginosa (P. aeruginosa). ... aztreonam lysine significantly improved,the time to need ...
... Demonstrated the Clinical Potential of Peregrine's,Unique Selective ... in Animal Cancer Models, TUSTIN, Calif., April ... a clinical stage,biopharmaceutical company developing targeted monoclonal ... C virus infection, today,reported that data from ...
Cached Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7
Designated most popular model or size. Slightly angled, 2 mm wide....
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
... AMO Prestige System marked an amazing ... of safety with high-performance fluidics.A.S.E.T. keeps ... conditions in the in the anterior ... the reaction and interaction of the ...
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
Medicine Products: